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Abstract
Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to 
sustain the oncogenic state1, but direct pharmacological inhibition of transcription factors has thus 
far proven difficult2. However, the transcriptional machinery contains various enzymatic co-
factors that can be targeted for development of new therapeutic candidates3, including cyclin-
dependent kinases (CDKs)4. Here we present the discovery and characterization of the first 
covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine 
residue located outside of the canonical kinase domain, providing an unanticipated means of 
achieving selectivity for CDK7. Cancer cell line profiling indicates that a subset of cancer cell 
lines, including T-ALL, exhibit exceptional sensitivity to THZ1. Genome-wide analysis in Jurkat 
T-ALL shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that 
sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and this 
transcription factor’s key role in the core transcriptional regulatory circuitry of these tumor cells. 
Pharmacological modulation of CDK7 kinase activity may thus provide an approach to identify 
and treat tumor types exhibiting extreme dependencies on transcription for maintenance of the 
oncogenic state.
In an effort to discover new inhibitors of kinases that regulate gene transcription, we 
performed cell-based screening and kinase selectivity profiling of a library of known and 
novel ATP-site directed kinase inhibitors (See Supplementary Table 1 for known CDK7 
inhibitors). We identified THZ1 (Fig. 1a), a phenylaminopyrimidine bearing a potentially 
cysteine-reactive acrylamide moiety, as a low nanomolar inhibitor of cell proliferation and 
biochemical CDK7 activity (Fig. 1b, c). To investigate the functional relevance of the 
acrylamide moiety we prepared a non-cysteine reactive analog THZ1-R, which displayed 
diminished activity for CDK7andreduced anti proliferative potency (Fig. 1b, c). KiNativ™ 
profiling5, which measures the ability of a compound to block nucleotide-dependent 
enzymes from biotinylation with a reactive desthiobiotin-ATP probe, established CDK7 as 
the primary intracellular target of THZ1, but not of THZ1-R (Supplementary Table 2). 
Kinome-wide profiling identified additional kinase targets of THZ1; however, we confirmed 
CDK7 as the only target displaying time-dependent inhibition, which is suggestive of 
covalent binding (Extended Data Fig. 1a–c and Supplementary Table 3).
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As no covalent inhibitors of CDKs have been reported, we next focused our studies on the 
mechanism by which THZ1 could achieve covalent inhibition of CDK7. We first incubated 
recombinant CDK7/cyclin H/MAT1 trimeric complex with a biotinylated version of THZ1 
(bio-THZ1, Fig. 1a) and demonstrated that it indeed covalently modifies CDK7 (Fig. 2a; 
Extended Data Fig. 1d–g). Mass spectrometry identified the site of covalent modification as 
C312, a residue located outside the kinase domain (Extended Data Fig. 2a–d). Inspection of 
the crystal structure reveals that a C-terminal extension of CDK7 bearing C312 traverses the 
ATP cleft in the kinase domain and would be predicted to position Cys312 directly adjacent 
to the reactive acrylamide moiety of THZ1 (Fig. 2b). Mutation to serine (C312S), a less 
nucleophilic amino acid, prevented THZ1 from covalently binding to CDK7 and from 
inhibiting CDK7 activity in an irreversible fashion (Fig. 2c; Extended Data Fig. 2e). 
Sequence alignment of the 20-member CDK family suggests that Cys312 is unique to 
CDK7, however CDK12 and CDK13 also possess accessible cysteines within 4 amino acids 
of Cys312 (Extended Data Fig. 3a). Indeed, we found that THZ1 can inhibit CDK12 kinase 
activity at slightly higher concentrations (Extended Data Fig. 3b–f). THZ1 is the first 
inhibitor demonstrated to target a cysteine located outside of the kinase domain, which 
provides an unanticipated means of achieving covalent selectivity.
CDK7 kinase activity has been implicated in the regulation of both transcription, where it 
phosphorylates the C-terminal domain (CTD) of RNAP polymerase II (RNAPII)6–8 and 
CDK99, and the cell cycle, where it functions as the CDK-activating kinase (CAK) for 
CDKs1/2/4/610–14. THZ1, but not THZ1-R, completely inhibits the phosphorylation of the 
established intracellular CDK7 substrate RNAPII CTD at Ser-5 and Ser-76,8, with 
concurrent loss of Ser-2 phosphorylation at 250 nM in Jurkat cells (Fig. 2d). Cellular 
washout experiments demonstrate that THZ1 indeed acts in an irreversible fashion (Fig. 2e, 
f; Extended Data Fig. 4a–e). We observed a loss of CAK activity, as evidenced by decreased 
phosphorylation of the activation loops of CDK1,2 and 9, indicating disruption of both 
recognized CDK7 signaling pathways in Jurkat cells (Fig. 2d; Extended Data Fig. 4f, g) and 
Loucy cell lines (Extended Data Fig. 4). Ectopic expression of dox-inducible FLAG-CDK7 
C312S, but not FLAG-CDK7 WT, in Hela S3 cells restored RNAPII CTD p-Ser 5/7 to near 
WT levels at concentrations of THZ1 up to 2.5 µM, establishing C312 as a critical 
determinant of the cellular pharmacology of the inhibitor (Extended Data Fig. 5a–b). 
Additionally, FLAG-CDK7 C312S expression restored CDK1/2 T-loop phosphorylation, 
reduced early induction of cleaved PARP and restored the expression of a subset of genes, 
including the highly –expressed transcription factors MYC, KLF4, ID1, and GATA2 
(Extended Data Fig. 5c–e). The partial rescues of the hyperphosphorylated form of RNAPII 
(RNAPII0) and RNAPII p-Ser2 CTD phosphorylation combined with the incomplete 
restoration of gene expression may result, in part, from lower affinity cross-reactivity of 
THZ1 with CDK12/13, which are bona fide Ser2 kinases15.
Our evidence that CDK7 inhibition leads to reduction in RNAPII CTD phosphorylation 
status appears in conflict with evidence that inhibition of CDK7 alone is insufficient to 
reduce RNAPII CTD phosphorylation in HCT116 cells9. It is possible that covalent 
inhibition and reversible inhibition can engender different effects on kinase structure; we did 
not find evidence that THZ1 impacts TFIIH or CAK complex stability (Extended Data Fig. 
4h). It is also possible that inhibition of CDK12/13 (or another undetected kinase) 
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contributes to reduced RNAPII CTD phosphorylation, although our evidence that RNAPII 
CTD phosphorylation levels are restored following expression of CDK7 C312S suggests 
otherwise.
To better understand the breadth of antiproliferative activity of THZ1, we screened it against 
a diverse panel of over 1,000 cancer cell lines16. THZ1 displayed broad-based activity with 
IC50s less than 200 nM against 53% of the cell lines tested (Fig. 3a; Supplementary Table 
4). Elastic net regression analysis incorporating gene expression, copy number, and 
sequence variation genomics data16 across 527 of the cell lines tested were used to identify 
genomic features common to sensitive cell lines. Gene ontology (GO) term enrichment 
analysis17 indicated a strong enrichment of (proto-) oncogenic transcription factors 
commonly overexpressed in cancer and factors involved in RNAPII-driven transcriptional 
regulation, suggesting the dominant activity of THZ1 was through modulation of 
transcription (Fig. 3b; Supplementary Table 5).
In agreement with the net elastic regression analysis, T-ALL cell lines that display 
characteristic misregulation of T-cell lineage-specific transcription factors, were broadly 
sensitive to THZ1, but not THZ1-R (Fig. 3c; Extended Data Fig. 6a and Supplementary 
Table 4). Treatment of T-ALL cell lines with THZ1 caused decreased cellular proliferation 
and an increase in apoptotic index with concomitant reduction in anti-apoptotic proteins, 
most notably MCL-1 and XIAP (Extended Data Fig. 6, 7). These strong anti proliferative 
responses induced at sub-effective doses of THZ1 suggest that these cells may be 
particularly sensitive to small perturbations in transcription and CDK7 kinase function. 
Indeed, THZ1 demonstrated efficacy against primary leukemia cells and in a bioluminescent 
xenografted model using the human T-ALL cell line, KOPTK1, when dosed twice daily 
(BID) at 10 mg/kg (Fig. 3d, e; Extended Data Fig. 8 and Supplementary Table 6). 
Importantly, THZ1 was well tolerated at these doses with no observable body weight loss or 
behavioral changes (Extended Data Fig. 8f), suggesting no overt toxicity to the animals. 
These results were mirrored in cell culture with non-transformed BJ fibroblast and retinal 
pigment epithelial (RPE-1) cells responding to relatively high doses of THZ1 by undergoing 
cell cycle arrest rather than initiating apoptosis or cell death, further suggesting that normal 
cells might tolerate transcriptional disruption (Extended Data Fig. 9).
CDK7 is a component of the general transcription factor IIH (TFIIH) complex18–20, so we 
next investigated how THZ1 treatment affects genome-wide gene expression. We chose 
Jurkat T-ALL for these studies because it a well-studied T-ALL cell line model with a 
defined core transcriptional regulatory circuitry, consisting of key transcription factors, 
which is also found in human T-ALL primagrafts21. Treatment with 250 nM THZ1, but not 
THZ1-R, led to progressive reduction in global steady-state mRNA levels over time, with 
75% and 96% of mRNAs showing greater than 2-fold reduction by 6 and 12 hrs, 
respectively (Fig. 4a, Extended Data Fig. 10a and Supplementary Table 7). Consistent with 
global downregulation of mRNA transcripts, 250 nM THZ1 reduced RNAPII occupancy 
genome-wide at both promoters and gene bodies (Fig. 4b). By comparison, Flavopiridol 
reduced RNAPII density across only gene bodies (Fig. 4b). This is consistent with the model 
that CDK7 regulates RNAPII initiation and pausing while CDK9 regulates pause release 
leading to processive elongation8,9,18–20,22–24.
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Although 250 nM THZ1 inhibits global transcription, we found that some cancer cell lines, 
particularly T-ALL, are sensitive to considerably lower concentrations of THZ1. We 
postulated that the expression of certain genes might be especially sensitive to low doses of 
THZ1 and therefore have a key role in driving the cellular response. Indeed, we found that 
transcripts for only a subset of genes were substantially affected by treatment with 50 nM 
THZ1, with that for RUNX1 among the most profoundly affected (Fig. 4c). There are at 
least two reasons that low dose THZ1 treatment might cause a preferential loss of RUNX1 
expression. Tumor cell oncogenes can acquire super-enhancers, which drive high-level 
expression yet can be especially sensitive to perturbation25–28. Super-enhancer analysis in 
Jurkat cells revealed that RUNX1 contains an exceptionally large super-enhancer domain 
containing a previously described hematopoietic cell –specific enhancer (Fig. 4d; Extended 
Data Fig. 10b–d and Supplementary Table 8)29. In addition, RUNX1 forms a core regulatory 
circuitry with two additional transcription factors that play prominent roles in leukemia 
biology, TAL1 and GATA3 (Fig. 4e)21. These factors auto regulate their own gene 
expression while simultaneously regulating many other genes that comprise the active gene 
expression program of Jurkat cells. Treatment with 50 nM THZ 1l ed to significant 
reduction in both the transcript and protein levels of RUNX1, TAL1, and GATA3 (Extended 
Data Fig. 10e and f). Loss of the RUNX1 driven transcriptional program is likely key to the 
response to low dose THZ1 treatment, as gene set enrichment analysis revealed that the 
Jurkat transcripts downregulated by 50 nM THZ1 were enriched in transcripts similarly 
downregulated following RUNX1 depletion using shRNA (Fig. 4f).
Here we have reported the discovery and characterization of the first covalent inhibitor of 
CDK7, THZ1. THZ1 employs a unique mechanism, combining ATP-site and allosteric 
covalent binding, as means of attaining potency and selectivity for CDK7. This mechanistic 
insight should be useful for designing next generation inhibitors of CDKs, where high 
sequence and shape homology in the ATP pocket has posed a formidable challenge to 
achieving selectivity with conventional ATP-competitive inhibitors. THZ1 displayed 
exquisite anti proliferative activity for T-ALL cell lines and other blood cancers, where 
oncogenic transcription factors feature prominently in the disease state.
In Jurkat cells, low dose THZ1 had a profound effect on a small subset of genes, including 
the key regulator RUNX1, thus contributing to subsequent loss of the greater gene 
expression program and cell death. Identification of additional cancer cell lines whose gene 
expression programs display vulnerability to THZ1 or other transcriptional inhibitors should 
delineate additional cancers that are exquisitely susceptible to perturbation of transcription.
Methods Summary
T-ALL culture conditions
Jurkat, Loucy, KOPTK1, and DND-41 cell lines were grown in RPMI-1640 supplemented 
with 10% fetal bovine serum and 1% glutamine. All cell lines were cultured at 37°C in a 
humidified chamber in the presence of 5% CO2, unless otherwise noted.
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Inhibitor treatment experiments
Time-course experiments such as those described in Extended Data Fig. 5a were conducted 
to determine the minimal time required for full inactivation of CDK7. Cells were treated 
with THZ1, THZ1-R, or DMSO for 0–6 hrs to assess the effect of time on the THZ1 –
mediated inhibition of RNAPII CTD phosphorylation. For subsequent experiments cells 
were treated with compounds for 4 hrs as determined by time-course experiment described 
above, unless otherwise noted. For inhibitor washout experiments (Fig. 2e, f; Extended Data 
Fig. 5) cells were treated with THZ1, THZ1-R, or DMSO for 4 hrs. Medium containing 
inhibitors was subsequently removed to effectively ‘washout’ the compound and the cells 
were allowed to grow in the absence of inhibitor. For each experiment, lysates were probed 
for RNAPII CTD phosphorylation and other specified proteins.
High-throughput cell line panel viability assay
Cells were seeded in 384-well microplates at ~15% confluency in medium with 5% FBS and 
penicillin/streptavidin. Cells were treated with THZ1 or DMSO for 72 hrs and cell viability 
was determined using resazurin.
RNA Extraction and Synthetic RNA Spike-In
Total RNA and sample preparation was performed as previously described30. Briefly, 
following inhibitor treatment cell number was determined, total RNA was isolated, and 
ERCC RNA Spike-In Mix (Ambion, cat# 4456740) was added to total RNA relative to cell 
number.
Expanded protocols and synthetic chemistry schemes can be found in Supplementary 
Information.
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Extended Data
Extended Data Figure 1. THZ1 demonstrates time-dependent inhibition of CDK7 in vitro and 
covalent binding of intracellular CDK7
a, THZ1 but not THZ1-R shows time-dependent inhibition. LanthaScreen® Eu Kinase 
Binding assay was conducted at Life Technologies in a time-dependent manner (20, 60, and 
180 min.) showing that THZ1 but not THZ1-R shows time-dependent inhibition of CDK7. b 
and c, Pre-incubation of THZ1 increases CDK7 inhibitory activity in vitro. Recombinant 
CAK complex was incubated with THZ1 (b) or THZ1-R (c) in dose response format with or 
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without pre-incubation prior to ATP (25 µM) addition. Kinase reaction was then allowed to 
proceed for 45 minutes at 30°C. d, Workflow of bio-THZ1 pull down competition 
experiment. e, bio-THZ1 pulls down CDK7 from cellular lysates. Loucy cellular lysates 
were incubated with bio-THZ1 (1 µM) with or without THZ1 (10 µM) and streptavidin-
precipitated proteins were probed for CDK7. IB = immunoblot. f, Free intracellular THZ1 
competes in a dose-dependent manner for bio-THZ1 binding to CDK7. Loucy cells were 
treated with increasing concentrations of THZ1 or with 10 µM THZ1-R for 4 hrs. Cellular 
lysates were incubated with bio-THZ1 and processed as indicated in a. g, bio-THZ1 labels 
CDK7 in lysates. Loucy cellular lysates were incubated with bio-THZ1 at 4°C for 12 hrs 
followed by immunoprecipitation of CDK7 at 4°C for 3 hrs. Precipitated proteins were 
washed and probed with streptavidin-HRP.
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Extended Data Figure 2. THZ1 covalently binds CDK7 C312
a and b, Total ion chromatograms (TIC) and extracted ion chromatograms (XIC) for CDK7 
peptides recorded during analysis of CAK complexes treated with DMSO (a) or THZ1 (b). 
c, Efficiency of labeling was estimated to be approximately 85% gauged by the reduction in 
signal of triply and quadruply charged YFSNRPGPTPGCQLPRPNCPVETLK ions 
(residues 294–318). The peptides VPFLPGDSDLDQLTR (residues 180–194) and 
LDFLGEGQFATVYK (residues 15–28) were used for normalization. d, Orbit rap HCD 
MS/MS spectrum of a quadruply charged CDK7 derived peptide (residues 294–318) labeled 
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by THZ1 at C312. Fragment ions containing the peptide C-terminus (y-type) or N-terminus 
(b-type), along with the associated mass errors are shown in red and blue, respectively. 
Fragment ions marked by (*) contain the inhibitor and have the expected heavy isotope 
contribution from chlorine. The site of labeling was determined to be C312 (as opposed to 
C305) based on fragment ions observed in additional MS/MS spectra (for example y113+ 
observed with < 3 ppm mass error by fragmentation of the +6 charged precursor; see inset 
mass spectrum). e, C312S mutation eliminates THZ1 covalent binding. Cellular lysates from 
HCT116 cells expressing either FLAG-CDK7 WT or C312S were incubated with bio-THZ1 
for 12 hrs at 4°C and then room temperature for 3 hrs to facilitate covalent binding. 
Precipitated proteins were then probed for the presence of FLAG-tagged CDK7.
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Extended Data Figure 3. THZ1 inhibits CDK12 but at higher concentrations compared to CDK7
a, Protein sequence alignment of the C-terminal regions of all human (hs) CDKs and mouse 
(m) CDK7 using Uniprot default settings. Note that the canonical cell cycle CDKs 1,2,4 as 
well as 5 do not have C-terminal domains that extent to the equivalent position of CDK7 
C312 and therefore do not display aligned sequence in this region. b, bio-THZ1 covalently 
pulls down CDK7 from cellular lysates. Jurkat cellular lysates were incubated with bio-
THZ1 (1 µM) at 4°C for 12 hrs and 2 hrs at room temperature. Precipitated proteins were 
washed with or without urea (4M), here used as a denaturing agent, and probed for the 
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indicated CDKs. c, bio-THZ1 pulls down FLAGCDK12 from lysates. Lysates from 293A 
cells stably expressing FLAG-tagged WT CDK12 were incubated with bio-THZ1 (1 µM) at 
4°C for 12 hrs and 2 hrs at rt. Immunoprecipitated proteins were probed with FLAG 
antibody to recognize CDK12 or with CDK7 antibody. d, bio-THZ1 pulls down cyclin K 
from cellular lysates. Jurkat cellular lysates were incubated with bio-THZ1 (1 µM) at 4°C 
for 12 hrs and 2 hrs at rt. Precipitated proteins were probed for the indicated proteins. e, 
THZ1 inhibits CDK12 in an in vitro kinase assay. 293A cells stably expressing FLAG-
tagged WT CDK12 were treated with THZ1 or THZ1-R for 4 hrs. Exogenous CDK12 was 
immunoprecipitated from cellular lysates using FLAG antibody. Precipitated proteins were 
washed and subjected to in vitro kinase assays at 30°C for 30 minutes using the large 
subunit of RNAPII (RPB1) as substrate and 25 µM ATP. CS = coomassie stain. f, 
Quantitation of in vitro kinase assay conducted in (d).
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Extended Data Figure 4. THZ1 irreversibly inhibits RNAPII CTD and CAK phosphorylation
a, THZ1 exhibits time-dependent inactivation of intracellular CDK7. Loucy cells were 
treated with THZ1 or THZ1-R for 0 to 4 hrs. At each time point cells were harvested, lysed, 
and the cellular lysates were probed with antibodies against the specified proteins. b, THZ1 
inhibits RNAPII CTD phosphorylation. Loucy cells were treated with THZ1 or THZ1-R for 
4 hrs. Cellular lysates were then probed with antibodies recognizing the Ser-2, Ser-5, and 
Ser-7 CTD RNAPII phosphoepitopes. c, Loucy cells were treated with THZ1 or THZ1-R for 
4 hrs followed by washout of inhibitor-containing medium. Cells were allowed to grow in 
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medium without inhibitor for 0 to 6 hrs. At each time point cells were lysed and the cellular 
lysates were probed with antibodies against the specified proteins. ‘N’ signifies cells where 
medium was never washed out. d, Apoptotic signaling is maintained despite washout of 
THZ1. Loucy cells were treated with THZ1 or THZ1-R for 4 hrs followed by washout of 
inhibitor-containing medium, at which point cells were allowed to grow in medium with or 
without inhibitor for 0 to 48 hrs. At each time point cells were lysed and the cellular lysates 
were probed with antibodies against the specified proteins. e, Anti proliferative effects of 
THZ1 are impervious to inhibitor washout. Loucy cells were treated with THZ1 or THZ1-R 
in dose response format for 72 hrs. Anti proliferative effects were determined using cell titer 
glo analysis. f, THZ1 reduces the T-loop phosphorylation status of CDK1 and CDK2 in 
Jurkat cells over a 3 hour exposure. Asynchronous cells were treated with increasing 
concentrations of THZ1 or THZ1-R for 3 hrs. Cellular lysates were then probed with 
antibodies against the indicated proteins or phosphoproteins. g, THZ1, but not THZ1-R, 
completely inhibits T-loop phosphorylation of CDK1 and CDK2 following treatment over 
one cell cycle. Loucy cells were treated with THZ1, THZ1-R, Flavopiridol, or DMSO 
vehicle at the indicated concentrations for 24 and 14 hrs, respectively (roughly one cell 
cycle). Cell lysates were harvested and probed with antibodies against the specified proteins 
or phosphoproteins. h, Hela S3 cells stably expressing FLAG-WT CDK7 were treated with 
THZ1 (1 µM) or DMSO vehicle for 5 hrs with and without the presence of doxycycline. 
Proteins were immunoprecipitated using FLAG antibody. Precipitated proteins were probed 
using the indicated antibodies. * indicates heavy-chain from IgG antibody.
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Extended Data Figure 5. Mutation of CDK7 Cys-312 to serine rescues Ser-5/7 and partially 
Ser2RNAPII CTD phosphorylation
a, Expression of C312S rescues Ser-5/7 and partially rescues Ser-2 RNAPII CTD 
phosphorylation. Hela S3 cells stably carrying a doxycycline-inducible FLAG-C312S CDK7 
construct were treated with THZ1 or DMSO for 5 hrs with and without the presence of 
doxycycline. Cellular lysates were then probed for the indicated proteins. b, Phenotypic 
rescue is specific to C312S mutation as rescue is not achieved with overexpression of 
FLAG-WT CDK7. Hela S3 cells stably carrying doxycycline-inducible FLAG-WT and 
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C312S CDK7 constructs (or empty vector) were treated with THZ1 or DMSO for 5 hrs in 
the presence of doxycycline. c, Expression of C312S largely restores CDK1/2 T-loop 
phosphorylation. Hela S3 cells stably carrying a doxycycline-inducible FLAG-C312S CDK7 
construct were treated with THZ1 or DMSO for 5 hrs with and without the presence of 
doxycycline. Cellular lysates were then probed for the indicated proteins or 
phosphoproteins. d, Overexpression of FLAG-CDK7 C312 rescues the expression of a 
subset of transcripts in Hela S3 cells. Log2 fold change in gene expression in Hela S3 cells 
expressing FLAG-CDK7 WT (x axis) and FLAG-CDK7 C312S (y axis) following a 4 hr 
treatment with 500 nM THZ1. e, Gene ontology molecular function analysis of transcripts 
increased by 1 log2 order or more following expression of FLAG-CDK7 C312S compared 
to FLAG-CDK7 WT in the presence of 500 nM THZ1.
Extended Data Figure 6. THZ1 potently disrupts T-ALL proliferation
a, THZ1, but not THZ1-R, exhibits strong antiproliferative effect against T-ALL cell lines. 
Cells were treated with THZ1, THZ1-R, or DMSO vehicle for 72 hrs and assessed for 
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antiproliferative effect by Cell Titer Glo analysis. Error bars are +/− SD. b, THZ1 causes 
cell cycle arrest. Jurkat (top) and Loucy (bottom) T-ALL cells were treated with THZ1 for 
the indicated time periods. Cell cycle progression was assessed using FACS cell cycle 
analysis. 2N = G1, 4N = G2. c, Treatment with THZ1 decreases CDK1/2 T loop 
phosphorylation. Jurkat cells were incubated with THZ1 for the indicated duration of time 
and lysates were probed for the specified proteins.
Extended Data Figure 7. Treatment with THZ1 induces apoptosis in T-ALL cells
Kwiatkowski et al. Page 17
Nature. Author manuscript; available in PMC 2015 January 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
a, Representative Annexin V and propidium iodide stainings for Jurkat cells incubated with 
THZ1 for the indicated amount of time and harvested to determine the percentage of 
apoptotic and/ or dead cells by Annexin V and propidium iodide staining, respectively. The 
percentage of cells in each cell population is shown in the four quadrants. b, Treatment with 
THZ1 induces apoptosis. Quantitation of Annexin V and propidium iodide staining data 
from a. Experiments were performed in biological triplicates and error bars are +/− SD. c, 
Representative Annexin V and propidium iodide stainings for Loucy cells incubated with 
THZ1 for the indicated amount of time and harvested to determine the percentage of 
apoptotic and/ or dead cells by Annexin V and propidium iodide staining, respectively. The 
percentage of cells in each cell population is shown in the four quadrants. d, Treatment with 
THZ1 induces apoptosis. Quantitation of Annexin V and propidium iodide staining data 
from c. Experiments were performed in biological triplicates and error bars are +/− SD. e 
and f, Sustained treatment with THZ1 induces apoptosis coincident with loss of RNAPII 
CTD phosphorylation and reduction in antiapoptotic proteins. Jurkat (e) and Loucy (f) cells 
were incubated with THZ1 for the indicated duration of time and lysates were probed for the 
specified proteins. Apoptosis was monitored by PARP cleavage.
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Extended Data Figure 8. THZ1 demonstrates potent killing of primary chronic lymphocytic 
leukemia (CLL) cells and anti-proliferative activity against primary TALL cells and in vivo 
against a human T-ALL xenograft
a, CLL cells were cultured in vitro for 24 hrs in the presence of multiple doses of the 
specified compound. Results shown are mean normalized % death based on Annexin V / PI 
single and double positive cells (+/− SD) normalized to baseline death in the DMSO control 
wells. 10 patient samples were exposed to THZ1, THZ1-R and Flavopiridol (THZ1 vs. 
THZ1-R p = 1.5E-38; THZ1 vs. Flavopiridol p = 0.05). P-values were generated using an 
analysis of variance model. b, Patient-derived xenografts (patient ID# 3255-1, M18-1-5, 
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D135-1-5; n=3) were treated with THZ1 for 3 hrs followed by compound washout. An 
aliquot of input cells was then counted by flow cytometry using a known quantity of flow 
cytometry calibration beads (data not shown; Molecular Probes). The remaining cells were 
plated onto MS5-DL1feeder cells in the presence of serum-free media (supplemented with 
0.75 µM SR1, 10 ng/ml IL7, 10 ng/ml IL2). 72 hrs later, cultures were harvested by vigorous 
pipetting with Trypsin, filtered through nylon mesh to deplete feeders, and counted by flow 
cytometry using a known quantity of flow cytometry calibration beads and with gating to 
discriminate between T-ALL cells and carryover feeders. The final cell number was 
normalized to the input cell number to calculate fold expansion. This experiment was 
performed once per patient- derived sample. c, Bioluminescent images of two representative 
mice treated with either vehicle control, 10 mg/kg THZ1 qD (once daily), or 10 mg/kg/day 
THZ1 BID (twice daily) for indicated number of days. d, Spleen tissue from mice treated 
with THZ1 show decreased RNAPII CTD phosphorylation. Mice were treated with THZ1 
10 mg/kg qD or BID or vehicle control. The animals were sacrificed and spleen tissues were 
isolated. Lysates prepared from homogenized spleen tissue were probed for RNAPII CTD 
phosphoepitopes. e, THZ1 binds directly to CDK7 in mouse tissues. Mice were treated with 
THZ1 10 mg/kg qD or BID or vehicle control. The animals were sacrificed and spleen 
tissues were isolated. Lysates prepared from homogenized spleen tissue were incubated with 
bio-THZ1 for 12 hrs at 4 °C and 2 hrs at rt to induce covalent bond formation. Proteins 
pulled down were then probed for the presence of CDK7. f, Bodyweights of mice treated 
with either vehicle control, 10 mg/kg THZ1 qD (once daily), or 10 mg/kg/day THZ1 BID 
(twice daily) over the duration of the drug treatment.
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Extended Data Figure 9. THZ1 inhibits RNAPII CTD phosphorylation and causes cell cycle 
arrest in non-transformed cell lines
a and b, THZ1 inhibits RNAPII CTD phosphorylation. RPE-1 (a), and BJ fibroblasts (b) 
were treated with THZ1 or THZ1-R for 4 hrs. Cellular lysates were then probed with 
antibodies against the indicated proteins. c and d, THZ1 causes cell cycle arrest in non-
transformed cells. RPE-1 (c) and BJ fibroblasts (d) cells were treated with THZ1, 
Flavopiridol, Staurosporine, or DMSO vehicle for the indicated time periods. Cell cycle 
progression was analyzed following permeabilization and staining with propidium iodide. e 
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and f, THZ1 inhibits proliferation of non-transformed cell lines. RPE-1 (e) and BJ 
fibroblasts (f) cells were treated with THZ1, THZ1-R, Flavopiridol, or Staurosporine for 72 
hrs and antiproliferative effect was determined by Cell Titer Glo. Error bars are +/− SD.
Extended Data Figure 10. High dose THZ1 reduces global steady-state mRNA levels, but low 
dose THZ1 preferentially downregulates components of the TAL1/RUNX1/GATA3 
transcriptional circuit
a, THZ1, but not THZ1-R, causes global downregulation of steady-state mRNA levels. 
Jurkat cells were treated with THZ1 (250 nM) or THZ1-R (250 nM) for 4 hrs. Total RNA 
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was isolated and ERCC spike-in controls were added relative to cell number and analyzed 
using Affymetrix Prime view microarrays. Heat maps displaying the Log 2 fold change in 
gene expression vs. DMSO for 22,310 genes expressed in DMSO conditions at 6h in THZ1 
or THZ1-R. b, Total H3K27Ac ChIP-seq signal (length * density) in enhancer regions for 
all stitched enhancers in Jurkat. Enhancers are ranked by increasing H3K27Ac ChIP-seq 
signal. c and d, Gene tracks of H3K27Ac (top), CDK7 (middle), and RNAPII (bottom) 
ChIP-seq occupancy at the TSS, gene body, and enhancer regions of TAL1 (c) and MYB (d). 
e, THZ1 downregulates mRNA transcripts of the TAL1/RUNX1/GATA3 transcriptional 
circuitry. RT-qPCR expression analysis in Jurkat cells of transcripts identified as 
downregulated following THZ1 treatment relative to DMSO. All experiments shown were 
performed in biological triplicate. Each individual biological sample was qPCR-amplified in 
technical triplicate. Error bars are +/− SD. Taqman universal expression probes and 
normalized to ACTB. f, THZ1 treatment reduces the protein levels of TAL1/RUNX1/
GATA3 transcriptional circuitry. Jurkat cells treated with THZ1 for the indicated time points 
were probed for the specified proteins.
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Figure 1. Cell-based screening and kinome profiling identifies phenylamino-pyrimidines as a 
potential CDK7 scaffold
a, Compound structures of THZ1, THZ1-R, and bio-THZ1. b, THZ1 potently inhibits 
proliferation of Jurkat and Loucy T-ALL cell lines. Cell lines were treated with THZ1 or 
THZ1-R for 72 hrs. Experiments were performed in biological triplicates and error bars are 
+/− SD. c, THZ1 and THZ1-R have different binding affinities for CDK7. LanthaScreen® 
Eu Kinase Binding assay was conducted at Life Technologies in a time-dependent manner. 
Here KD values are shown following 180-minute incubation with compounds. Experiments 
were performed in biological triplicates and error bars are +/− SD.
Kwiatkowski et al. Page 25
Nature. Author manuscript; available in PMC 2015 January 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. THZ1 irreversibly inhibits RNAPII CTD phosphorylation by covalently targeting a 
unique cysteine located outside the kinase domain of CDK7
a, bio-THZ1 binds irreversibly to CDK7. Recombinant CAK complex was incubated with 
bio-THZ1 +/− THZ1 at 37°C for 4 hrs and biotinylated proteins were resolved by SDS-page. 
b, Docking model of THZ1 in the ATP-binding pocket of CDK7 (PDB code 1UA2). CDK7 
depicted with grey ribbons and THZ1 in turquois. Key residues are indicated. C312 has been 
modeled into the crystal structure. c, Mutation of C312 to serine (C312S) rescues wild-type 
kinase activity in the presence of THZ1. HCT116 cells stably expressing FLAG-tagged 
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CDK7 proteins were treated with THZ1 or THZ1-R for 4 hrs. Exogenous CDK7 proteins 
were immunoprecipitated with FLAG antibody and subjected to in vitro kinase assays. CS = 
coomassie stain. d, THZ1 inhibits RNAPII CTD phosphorylation. Jurkat cells were treated 
with THZ1 or THZ1-R for 4 hrs. and proteins of interest resolved by SDS page. e, THZ1, 
but not THZ1-R, shows irreversible inactivation of CDK7. Jurkat cells were treated with 
THZ1 or THZ1-R for 4 hrs followed by washout of inhibitor-containing medium. Cells were 
then allowed to grow in medium without inhibitor for 0 to 6 hrs. ‘N’ signifies cells where 
medium was never washed out (ie – 10 hr incubation with compounds). f, Anti proliferative 
effects of THZ1 are impervious to inhibitor washout. Jurkat cells were treated with THZ1 or 
THZ1-R in dose response format for 72 hrs. Experiments were performed in biological 
triplicates and error bars are +/− SD.
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Figure 3. THZ1 strongly reduces the proliferation and cell viability of T-ALL cell lines
a, THZ1 exhibits strong anti proliferative effect across a broad range of cancer cell lines 
from various cancer types. Cells were treated with THZ1 or DMSO vehicle for 72 hrs and 
assessed for anti proliferative effect using resazurin. b, Overexpression of transcriptional 
regulators, including (proto) oncogenic transcription factors, is a strong predictor of cell line 
sensitivity to THZ1. GO terms associated with overexpressed factors found in THZ1 –
sensitive cell lines. c, THZ1 exhibits strong anti proliferative affect against T-ALL cell lines. 
BJ fibroblasts and RPE-1 cells are shown as normal cell lines. Cells were treated with THZ1 
or DMSO vehicle for 72 hrs. Experiments were performed in biological triplicates and error 
bars are +/− SD. d, THZ1 reduces the proliferation of KOPTK1 T-ALL cells in a human 
xenograft mouse model. Bioluminescent images of two representative mice treated with 
either vehicle control, 10 mg/kg THZ1 qD (once daily), or 10 mg/kg/day THZ1 BID (twice 
daily) for 29 days. e, Relative bioluminescence (BLI) of mice treated with vehicle, 10 mg/kg 
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THZ1 qD (once daily), or 10 mg/kg/day THZ1 BID (twice daily) during the 29 days of 
treatment. n=10 for all groups. Bioluminescence is shown relative to day 0 and is plotted as 
average ± SEM. Analysis of the BLI data by repeated measures (RM) two-way ANOVA 
reveals the anti-proliferative effect of treatment with THZ1 BID is highly statistically 
significantly different (p<0.0001) as compared to the other treatments.
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Figure 4. THZ1 preferentially downregulates Jurkat core transcriptional circuitry
a, THZ1 treatment globally downregulates steady-state mRNA levels in a time-dependent 
manner. Jurkat cells were treated with THZ1 (250 nM) for the indicated amounts of time. 
Heatmaps display the Log2 fold change in gene expression vs. DMSO for the 21,970 
transcripts expressed at 12h in DMSO. b, THZ1 reduces RNAPII occupancy across 
promoters and gene bodies. Meta gene representation of global RNAPII occupancy at 
promoters and gene bodies (top). Average background subtracted ChIP-seq signal in 22,310 
genes expressed in 6 h DMSO conditions in units of rpm/bp. Gene tracks of RNAPII ChIP-
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seq occupancy at RUNX1 following the indicated treatments (bottom). Signal of ChIP-seq 
occupancy is in units of reads per million (rpm). All treatments were 6 hrs with 250 nM of 
THZ1, THZ1-R, or Flavopiridol. c, THZ1 treatment delineates a subset of transcripts 
equally sensitive to low dose (50 nM) THZ1. Log2 fold change in gene expression for 50 
nM (x axis) and 250 nM THZ1 (y axis) following a 4 hr treatment. Pearson coefficient r = 
0.50. d, Gene tracks of H3K27Ac (top), CDK7 (middle), and RNAPII (bottom) ChIP-seq 
occupancy at the TSS, gene body, and a previously described enhancer region in the first 
intron of RUNX129. Total ChIP-seq signal is in units of rpm. e, Positive interconnected 
autoregulatory loop formed by RUNX1, TAL1, and GATA3. Genes are represented by 
rectangles, and proteins are represented by ovals21. f, Transcripts down-regulated by low 
dose THZ1 are enriched for transcripts downregulated following RUNX1 knockdown. Gene 
set enrichment analysis of top 500 transcripts downregulated following a 4-hour treatment 
with THZ1 (50 nM) in comparison to transcripts following a RUNX1 knockdown21. GSEA-
supplied p-value < 0.001.
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